Expert Consensus: American College of Physicians: GLP-1 receptor agonists should be considered for patients with obesity who have not achieved weight loss goals with lifestyle modifications. Endocrine Society: Semaglutide and tirzepatide represent significant advances in obesity pharmacotherapy and should be considered first-line options. Obesity Medicine Association: The dramatic efficacy of GLP-1 and dual agonist medications has fundamentally changed the treatment landscape for obesity. Real-World Effectiveness: Studies of patients using these medications outside clinical trials show: GLP-1s: Similar to clinical trial results (confirming real-world effectiveness) Older medications: Often less effective in real-world than trials (adherence issues) Patient satisfaction: Highest with GLP-1s Bottom Line: Which Works Best

In combination with its excellent bioavailability in the central nervous system, these properties have led to the compound gaining interest from the scientific community for the treatment of neurodegenerative diseases
Therefore, this could be clearly generalized, and thus, its own effect unmistakably ascribed only to the given peptide (for review, see Seiwerth et al., 2018)
Compounded semaglutide may also be prescribed when medically appropriate
[4] [6] The proposed mechanism involves rapid weight loss leading to changes in bile composition and gallbladder motility
BPA is a xenoestrogen that affects the hypothalamicpituitarygonadal (HPG) axis and testosterone synthesis and produces oxidative stress in male reproductive organs, such as the testes and epididymis (Liu et al., 2021